Genetic spectrum of unexplained neonatal seizures: a single-center study
Authors:
- Zhiyong LiuZLZhiyong Liu
- Ying HeYHYing He
- Junzi HuangJHJunzi Huang
- Hongyuan YangHYHongyuan Yang
- Yanling ZengYZYanling Zeng
- Lanju YuLYLanju Yu
- Tianfeng ChenTCTianfeng Chen
- Lin WangLWLin Wang
- Cheng CaiCCCheng Cai
- Ruiquan WangRWRuiquan Wang
- Lianqiang WuLWLianqiang Wu
- Jinglin XuJXJinglin Xu
Open Access
- 1 February 2026
- journal article
- Published by AME Publishing Company in Translational Pediatrics
- Vol. 15 (2) , 43
Abstract
Up to 40% of neonatal seizures remain unexplained after standard evaluation, creating a diagnostic imperative. Distinguishing genetic etiologies is critical, as it enables the identification of treatable conditions and informs prognosis and family counseling. In this study, we aimed to define the genetic spectrum of unexplained neonatal seizures in a Chinese cohort. In this single-center retrospective case series, we enrolled 40 neonates [2016–2024] admitted to the neonatal intensive care unit with video electroencephalography (vEEG)-confirmed seizures that were “unexplained” after a comprehensive evaluation including neuroimaging and metabolic screening. Exclusion criteria included identified causes such as hypoxic-ischemic encephalopathy or confirmed metabolic disorders. Genetic analysis involved whole-exome sequencing (WES), clinical exome sequencing (CES), WES of patient and parents (trio) (trio-WES), and mitochondrial DNA analysis. The cohort included 29 male and 11 female neonates, with a median seizure onset at 1.5 days of life. Pathogenic or likely pathogenic variants were detected in 67.5% (27/40) of cases, including, but not limited to, variants in KCNQ2, ALDH7A1, and SUOX. A dual diagnosis was identified in one individual with compound heterozygous SUOX mutations and a de novo TUBG1 deletion. Additionally, nine of the 28 identified variants were novel. Although diagnostic yields varied among methodologies, the differences were not significant. Three patients with ALDH7A1 mutations achieved seizure freedom with vitamin B6 alone. All patients with SUOX nonsense/frameshift mutations had severe phenotypes and poor outcomes. Our findings demonstrate a high diagnostic yield of next-generation sequencing (NGS) in unexplained neonatal seizures and underscore its clinical utility in pinpointing treatable conditions and prognosticating severe disorders.Keywords
This publication has 30 references indexed in Scilit:
- De novo NSF mutations cause early infantile epileptic encephalopathyAnnals of Clinical and Translational Neurology, 2019
- Clinical Application of Targeted Next-Generation Sequencing Panels and Whole Exome Sequencing in Childhood EpilepsyNeuroscience, 2019
- Genomic backgrounds of Japanese patients with undiagnosed neurodevelopmental disordersBrain and Development, 2019
- Adapting ACMG/AMP sequence variant classification guidelines for single-gene copy number variantsGenetics in Medicine, 2019
- Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 IndividualsThe American Journal of Human Genetics, 2019
- TUBG1 missense variants underlying cortical malformations disrupt neuronal locomotion and microtubule dynamics but not neurogenesisNature Communications, 2019
- Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet Neurology, 2019
- Isolated sulfite oxidase deficiencyJournal of Inherited Metabolic Disease, 2017
- Profile of neonatal epilepsiesNeurology, 2017
- Advances in epilepsy gene discovery and implications for epilepsy diagnosis and treatmentCurrent Opinion in Neurology, 2017